Sunesis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNSS)

$5.97 -0.06 (-1.00 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$5.97
Today's Range$5.85 - $6.09
52-Week Range$1.82 - $6.24
Volume144,475 shs
Average Volume138,511 shs
Market Capitalization$202.43 million
P/E Ratio-3.41
Dividend YieldN/A
Beta1.71

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:SNSS
CUSIP86732860
Phone+1-650-2663500

Debt

Debt-to-Equity Ratio-0.34%
Current Ratio1.84%
Quick Ratio1.84%

Price-To-Earnings

Trailing P/E Ratio-3.41142857142857
Forward P/E Ratio-3.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.54 million
Price / Sales80.50
Cash FlowN/A
Price / CashN/A
Book Value$0.11 per share
Price / Book54.27

Profitability

Trailing EPS($1.75)
Net Income$-38,020,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-125.56%

Miscellaneous

Employees37
Outstanding Shares34,250,000

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.06. During the same quarter last year, the firm earned ($0.62) EPS. View Sunesis Pharmaceuticals' Earnings History.

When will Sunesis Pharmaceuticals make its next earnings announcement?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Sunesis Pharmaceuticals.

Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2018?

4 brokers have issued 1 year price targets for Sunesis Pharmaceuticals' stock. Their forecasts range from $2.48 to $7.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $4.16 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.

What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (2/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "SNSS provided an update on vecabrutinib (SNS-062), in development for r/r B- cell malignancies, including CLL, disclosing patient level data for the 25 mg dose cohort (n=3) that suggests that the drug has activity consistent with its mechanism and attributes." (12/11/2017)
  • 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:

  • Dayton C. Misfeldt, Interim Chief Executive Officer, Director (Age 44)
  • William Quinn, Chief Financial Officer, Senior Vice President - Finance and Corporate Development
  • Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer (Age 51)
  • James W. Young Ph.D., Non-Executive Independent Chairman of the Board
  • Stephen B. Ketchum Ph.D., Director (Age 50)
  • H. Ward Wolff, Director (Age 68)
  • Steve R. Carchedi, Independent Director (Age 55)
  • Matthew K. Fust, Independent Director (Age 52)

Who owns Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Vatera Holdings LLC (0.53%), BlackRock Inc. (0.38%), Geode Capital Management LLC (0.37%) and Wells Fargo & Company MN (0.14%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Who sold Sunesis Pharmaceuticals stock? Who is selling Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Sunesis Pharmaceuticals.

Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vatera Holdings LLC, Geode Capital Management LLC and BlackRock Inc.. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $5.97.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $202.43 million and generates $2.54 million in revenue each year. The biopharmaceutical company earns $-38,020,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 37 workers across the globe.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 Oyster Point Blvd Ste 400, SOUTH SAN FRANCISCO, CA 94080-1995, United States. The biopharmaceutical company can be reached via phone at +1-650-2663500 or via email at [email protected]


MarketBeat Community Rating for Sunesis Pharmaceuticals (SNSS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sunesis Pharmaceuticals (NASDAQ:SNSS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.502.502.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.16$4.16$3.00$3.00
Price Target Upside: 24.55% upside24.55% upside17.19% upside14.07% upside

Sunesis Pharmaceuticals (NASDAQ:SNSS) Consensus Price Target History

Price Target History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ:SNSS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/14/2017OppenheimerInitiated CoverageBuy$7.00LowView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetHold$3.00HighView Rating Details
12/11/2017Wells Fargo & CoUpgradeMarket Perform -> Outperform$2.86 -> $2.48HighView Rating Details
11/2/2017CowenReiterated RatingHoldN/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings History and Estimates Chart

Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ SNSS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.29)N/AView Earnings Details
11/2/2017Q3 2017($0.37)($0.43)$0.37 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.76)($0.41)$2.40 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
3/14/2012Q4 2011($1.14)($1.14)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.84)($0.23)ViewN/AView Earnings Details
3/29/2011Q4 2010($0.60)($1.38)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.72)($0.83)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.44)($2.63)ViewN/AView Earnings Details
4/29/2010Q1 2010($4.32)($3.89)ViewN/AView Earnings Details
3/30/2010Q4 2009($5.76)($5.40)ViewN/AView Earnings Details
11/16/2009Q3 2009($5.04)($5.11)ViewN/AView Earnings Details
7/29/2009Q2 2009($5.76)($29.54)ViewN/AView Earnings Details
5/6/2009Q1 2009($10.44)($6.80)ViewN/AView Earnings Details
4/1/2009Q4 2008($6.84)($7.23)ViewN/AView Earnings Details
11/4/2008Q3 2008($11.88)($7.41)ViewN/AView Earnings Details
8/7/2008Q2 2008($15.83)($14.18)ViewN/AView Earnings Details
5/8/2008Q1 2008($10.08)($10.08)ViewN/AView Earnings Details
3/11/2008Q4 2007($8.64)($9.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.58 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 39.46%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Mpm Oncology Impact ManagementMajor ShareholderBuy81,500$2.77$225,755.00View SEC Filing  
11/2/2017Mpm Oncology Impact ManagementMajor ShareholderBuy25,300$2.59$65,527.00View SEC Filing  
10/27/2017Dayton MisfeldtDirectorBuy400,000$2.00$800,000.00View SEC Filing  
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.8065,151View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.0062,005View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.3530,000View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16179,510View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84179,510View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sunesis Pharmaceuticals (NASDAQ SNSS) News Headlines

Source:
DateHeadline
Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 15 at 2:08 PM
Sunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment ResearchSunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 2:16 PM
Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of DirectorsSunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
finance.yahoo.com - February 8 at 8:29 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by AnalystsSunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 4 at 11:14 AM
-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - January 29 at 1:10 AM
Reviewing Fibrocell Science (FCSC) and Sunesis Pharmaceuticals (SNSS)Reviewing Fibrocell Science (FCSC) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - January 15 at 5:10 PM
Sunesis Pharmaceuticals (SNSS) and PRA Health Sciences (PRAH) Head to Head ContrastSunesis Pharmaceuticals (SNSS) and PRA Health Sciences (PRAH) Head to Head Contrast
www.americanbankingnews.com - January 14 at 3:58 AM
Financial Survey: WuXi PharmaTech (Cayman) (WX) versus Sunesis Pharmaceuticals (SNSS)Financial Survey: WuXi PharmaTech (Cayman) (WX) versus Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - January 13 at 11:34 PM
Sunesis Pharmaceuticals, Inc. (SNSS) Expected to Announce Earnings of -$0.25 Per ShareSunesis Pharmaceuticals, Inc. (SNSS) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 12 at 3:14 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Rating of "Hold" by BrokeragesSunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 10 at 8:18 AM
Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike HigherMid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher
www.nasdaq.com - January 4 at 3:27 PM
Zacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per ShareZacks: Brokerages Expect Sunesis Pharmaceuticals, Inc. (SNSS) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - December 26 at 4:07 PM
-$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter-$0.25 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - December 26 at 4:07 PM
Reviewing Sunesis Pharmaceuticals (SNSS) and Synageva Biopharma (GEVA)Reviewing Sunesis Pharmaceuticals (SNSS) and Synageva Biopharma (GEVA)
www.americanbankingnews.com - December 24 at 3:22 AM
Stocks to watch next week - Apple Inc. (NASDAQ:AAPL) | Seeking ... - Seeking AlphaStocks to watch next week - Apple Inc. (NASDAQ:AAPL) | Seeking ... - Seeking Alpha
seekingalpha.com - December 23 at 9:13 PM
Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of "Hold" from AnalystsSunesis Pharmaceuticals, Inc. (SNSS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 16 at 8:46 AM
Sunesis Pharmaceuticals (SNSS) Now Covered by OppenheimerSunesis Pharmaceuticals (SNSS) Now Covered by Oppenheimer
www.americanbankingnews.com - December 14 at 3:26 PM
Pre-Open Movers 12/11: (BLUE) (BPMC) (SNSS) Higher; (SYRS) (ONCE) (GBT) Lower (more...)Pre-Open Movers 12/11: (BLUE) (BPMC) (SNSS) Higher; (SYRS) (ONCE) (GBT) Lower (more...)
www.streetinsider.com - December 13 at 3:28 PM
ARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNAARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNA
www.nasdaq.com - December 12 at 3:27 PM
Wells Fargo Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to ... - StreetInsider.comWells Fargo Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to ... - StreetInsider.com
www.streetinsider.com - December 12 at 8:56 AM
Sunesis Pharmaceuticals (SNSS) Upgraded at Wells Fargo & CompanySunesis Pharmaceuticals (SNSS) Upgraded at Wells Fargo & Company
www.americanbankingnews.com - December 11 at 7:52 PM
Sunesis Pharmaceuticals (SNSS) PT Set at $3.00 by Cantor FitzgeraldSunesis Pharmaceuticals (SNSS) PT Set at $3.00 by Cantor Fitzgerald
www.americanbankingnews.com - December 11 at 9:46 AM
Top Analyst Upgrades and Downgrades: ADP, Bluebird Bio, DaVita, First Solar, Square, SunPower, US Steel and MoreTop Analyst Upgrades and Downgrades: ADP, Bluebird Bio, DaVita, First Solar, Square, SunPower, US Steel and More
247wallst.com - December 11 at 9:31 AM
Sunesis Pharmaceuticals (SNSS) and Its Peers Head-To-Head ComparisonSunesis Pharmaceuticals (SNSS) and Its Peers Head-To-Head Comparison
www.americanbankingnews.com - December 5 at 11:36 PM
Sunesis Pharmaceuticals to Provide Program Update for Non ... - GlobeNewswire (press release)Sunesis Pharmaceuticals to Provide Program Update for Non ... - GlobeNewswire (press release)
globenewswire.com - December 5 at 3:27 PM
Sunesis Pharmaceuticals Announces Change in Leadership - GlobeNewswire (press release)Sunesis Pharmaceuticals Announces Change in Leadership - GlobeNewswire (press release)
globenewswire.com - December 5 at 3:27 PM
Wells Fargo Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform - StreetInsider.comWells Fargo Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform - StreetInsider.com
www.streetinsider.com - December 5 at 3:27 PM
Sunesis Pharmaceuticals (SNSS) Given a $3.00 Price Target by Cantor Fitzgerald AnalystsSunesis Pharmaceuticals (SNSS) Given a $3.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 5 at 10:34 AM
Top Analyst Upgrades and Downgrades: Bluebird Bio, Delphi, DowDuPont, Expedia, McDonald’s, Snap, Ulta, Vale and MoreTop Analyst Upgrades and Downgrades: Bluebird Bio, Delphi, DowDuPont, Expedia, McDonald’s, Snap, Ulta, Vale and More
247wallst.com - December 5 at 9:00 AM
Sunesis Pharmaceuticals Announces Change in LeadershipSunesis Pharmaceuticals Announces Change in Leadership
finance.yahoo.com - December 5 at 8:59 AM
Wells Fargo & Company Lowers Sunesis Pharmaceuticals (SNSS) to Market PerformWells Fargo & Company Lowers Sunesis Pharmaceuticals (SNSS) to Market Perform
www.americanbankingnews.com - December 5 at 7:58 AM
Comparing Sunesis Pharmaceuticals (SNSS) and Its RivalsComparing Sunesis Pharmaceuticals (SNSS) and Its Rivals
www.americanbankingnews.com - December 4 at 1:28 PM
Analyzing Sunesis Pharmaceuticals (SNSS) and Its PeersAnalyzing Sunesis Pharmaceuticals (SNSS) and Its Peers
www.americanbankingnews.com - December 4 at 8:44 AM
Sunesis Pharmaceuticals (SNSS) Names William Quinn as CFO - StreetInsider.comSunesis Pharmaceuticals (SNSS) Names William Quinn as CFO - StreetInsider.com
www.streetinsider.com - December 1 at 11:46 AM
Sunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate DevelopmentSunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development
feeds.benzinga.com - November 30 at 7:52 AM
UPDATE: Oppenheimer Starts Sunesis Pharmaceuticals Inc. (SNSS) at Outperform - StreetInsider.comUPDATE: Oppenheimer Starts Sunesis Pharmaceuticals Inc. (SNSS) at Outperform - StreetInsider.com
www.streetinsider.com - November 23 at 12:58 PM
Research Analysts Set Expectations for Sunesis Pharmaceuticals, Inc.s FY2017 Earnings (SNSS)Research Analysts Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - November 23 at 7:28 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Receives Average Recommendation of "Hold" from AnalystsSunesis Pharmaceuticals, Inc. (SNSS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 21 at 3:38 PM
Sunesis Pharmaceuticals, Inc. (SNSS) Research Coverage Started at Oppenheimer Holdings, Inc.Sunesis Pharmaceuticals, Inc. (SNSS) Research Coverage Started at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 21 at 2:38 PM
Sunesis Pharmaceuticals, Inc. (SNSS) Earns Outperform Rating from Analysts at UBS AGSunesis Pharmaceuticals, Inc. (SNSS) Earns Outperform Rating from Analysts at UBS AG
www.americanbankingnews.com - November 20 at 7:32 PM
Head to Head Survey: Sunesis Pharmaceuticals (SNSS) & The CompetitionHead to Head Survey: Sunesis Pharmaceuticals (SNSS) & The Competition
www.americanbankingnews.com - November 20 at 3:20 PM
Comparing United Therapeutics Corporation (UTHR) and Sunesis Pharmaceuticals (SNSS)Comparing United Therapeutics Corporation (UTHR) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - November 17 at 5:06 PM
Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)
finance.yahoo.com - November 16 at 8:35 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Expected to Post FY2017 Earnings of ($1.66) Per ShareSunesis Pharmaceuticals, Inc. (SNSS) Expected to Post FY2017 Earnings of ($1.66) Per Share
www.americanbankingnews.com - November 8 at 10:36 AM
Insider Buying: Sunesis Pharmaceuticals, Inc. (SNSS) Major Shareholder Buys 25,300 Shares of StockInsider Buying: Sunesis Pharmaceuticals, Inc. (SNSS) Major Shareholder Buys 25,300 Shares of Stock
www.americanbankingnews.com - November 7 at 12:28 AM
Insider Buying: Sunesis Pharmaceuticals, Inc. (SNSS) Major Shareholder Buys 81,500 Shares of StockInsider Buying: Sunesis Pharmaceuticals, Inc. (SNSS) Major Shareholder Buys 81,500 Shares of Stock
www.americanbankingnews.com - November 7 at 12:28 AM
Sunesis reports 3Q lossSunesis reports 3Q loss
finance.yahoo.com - November 4 at 4:24 PM
Edited Transcript of SNSS earnings conference call or presentation 2-Nov-17 6:00pm GMTEdited Transcript of SNSS earnings conference call or presentation 2-Nov-17 6:00pm GMT
finance.yahoo.com - November 4 at 4:24 PM
Sunesis Pharmaceuticals (SNSS) "Hold" Rating Reaffirmed at Cowen and CompanySunesis Pharmaceuticals' (SNSS) "Hold" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - November 2 at 4:32 PM
Sunesis Pharmaceuticals, Inc. (SNSS) Issues  Earnings Results, Misses Estimates By $0.06 EPSSunesis Pharmaceuticals, Inc. (SNSS) Issues Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - November 2 at 2:36 PM

SEC Filings

Sunesis Pharmaceuticals (NASDAQ:SNSS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sunesis Pharmaceuticals (NASDAQ:SNSS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sunesis Pharmaceuticals (NASDAQ SNSS) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.